InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
04 avr. 2019 06h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
03 avr. 2019 16h05 HE
|
InspireMD, Inc.
TEL AVIV, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces 1-for-50 Reverse Stock Split
26 mars 2019 07h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and...
InspireMD Provides Amended Disclosure
22 mars 2019 18h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Fourth Quarter 2018 Financial Results
19 févr. 2019 07h00 HE
|
InspireMD, Inc.
2018 CGuard™ EPS annual sales increased 55% compared to 2017 On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, Feb. 19, 2019 (GLOBE...
InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19
07 févr. 2019 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent
24 janv. 2019 08h00 HE
|
InspireMD, Inc.
CGuard™ EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard™ arm Data presented at the LINC 2019 Congress in Leipzig,...
InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2019
23 janv. 2019 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 23, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFit™ Technology
22 janv. 2019 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany
18 janv. 2019 09h34 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...